Analysis of circulating RNA in the plasma of pregnant women has the potential to serve as a powerful tool for noninvasive prenatal testing and research. However, detection of circulating RNA in the plasma in an unbiased and high-throughput manner has been technically challenging. Therefore, only a limited number of circulating RNA species in maternal plasma have been validated as pregnancy-and placentaspecific biomarkers.
The presence of cell-free fetal RNA in maternal plasma was reported more than a decade ago (1 ) . Many studies have since been conducted to detect circulating RNA of fetal and placental origin in maternal plasma (2) (3) (4) . Interestingly, the expression levels of placenta-specific transcripts in the plasma positively correlated with those in placental tissues (3 ) , underscoring the potential clinical utility of plasma RNA analysis as a noninvasive tool to monitor placental development and fetal health. Examination of maternal circulating RNA has found clinical applications for pregnancy-or placentarelated disorders such as preeclampsia (5) (6) (7) (8) , intrauterine growth retardation (9 ) , and preterm birth (10 ) , as well as for noninvasive testing of fetal chromosomal aneuploidies (11) (12) (13) . Such developments highlight the potential utilities of RNA biomarkers for the molecular assessment of prenatal disorders.
Despite the promising outlook of plasma RNA analysis in prenatal testing, there remain a limited number of well-validated pregnancy-or placentarelated transcripts in maternal plasma to date. In this regard, examination of RNA biomarkers in the plasma has been conducted using reverse transcriptase-PCR (2-4, 6, 9, 10 ) , an analytically sensitive method that can typically target a relatively small number of RNA species per analysis. Of note, these studies have mainly focused on genes with relatively high levels of expression in the placenta compared with maternal blood cells, on the premise that pregnancy-associated genes are largely derived from the placenta. Such approaches have identified pregnancy-associated RNA targets that are highly expressed in the placenta but might have missed other important targets. Furthermore, given the low concentrations and poor integrity of plasma RNA (8, 14 ) , conventional high-throughput methods such as serial analysis of gene expression and microarray analysis would not be robust for the direct examination of the plasma transcriptome.
The aforesaid technical limitations of plasma RNA analysis could potentially be resolved by employing massively parallel sequencing (MPS) 4 for RNA analysis, namely RNA sequencing (RNA-seq) (15, 16 ) . Given the enhanced analytical sensitivity and wide dynamic range, RNA-seq has been employed to examine gene expression in many human tissues, including the placenta (17 ) . The superiority of MPS has been further demonstrated by its feasibility in direct profiling of plasma microRNAs in healthy individuals (18 ) and in pregnant women (19, 20 ) . Nevertheless, the full spectrum of the plasma transcriptome remains elusive, which might be due to the lower stability of long RNA species compared to short microRNAs in the plasma (21 ) .
In this proof-of-concept study, we have shown that fetal-and maternal-derived transcripts can be detected in maternal plasma and that their relative contributions can be estimated using RNA-seq, by examination of fetal-and maternal-specific single-nucleotide polymorphisms (SNPs). In addition, the allele-specific expression (ASE) patterns of the placenta can be monitored in maternal plasma. We have also demonstrated that pregnancy-associated transcripts can be identified by direct examination of the maternal plasma before and after delivery.
Materials and Methods

CASE RECRUITMENT AND SAMPLE COLLECTION
We recruited 1 first-, 1 second-, and 2 third-trimester pregnant women with singleton pregnancies from the Department of Obstetrics and Gynaecology, Prince of Wales Hospital, Hong Kong. For the first-and secondtrimester pregnant women, categorized as "early pregnancy cases," we collected peripheral blood, as well as chorionic villi or amniotic fluid; for the third-trimester pregnant women, categorized as "late pregnancy cases," we collected peripheral blood before cesarean delivery and at 24 h after delivery, as well as the delivered placental tissues. Peripheral blood samples from 20 additional third-trimester pregnant women and 2 nonpregnant females were also collected. The study was approved by the Clinical Research Ethics Committee of The Chinese University of Hong Kong. All subjects were recruited with written informed consent. Details for sample collection are described in the Data Supplement that accompanies the online version of this report at http://www.clinchem. org/content/vol60/issue7.
SAMPLE PROCESSING AND LIBRARY SEQUENCING
Total RNA was extracted from the maternal blood cells, placenta, and plasma. A summary of samples analyzed by RNA-seq is shown in online Supplemental Table 1 . Placental and blood cell RNA samples were pretreated with a Ribo-Zero Gold Kit (Epicentre) to remove ribosomal RNA (rRNA) before sequencing library preparation. Plasma samples of case 9356 were pretreated with a Ribo-Zero Gold Kit, but owing to a high GC bias, Ribo-Zero Gold pretreatment was omitted for all other plasma samples (see Results in the online Supplemental Data file). Maternal blood cell and placental RNA samples were subjected to chemical fragmentation for 5 min; the fragmentation time was reduced to 2.5 min for plasma RNA samples. cDNA libraries were synthesized using the mRNA-Seq sample preparation kit (Illumina), following the manufacturer's instructions with slight modification, and were sequenced for 50 bp or 75 bp in a paired-end format on a HiSeq 2000 instrument (Illumina). Genomic DNA was extracted from the peripheral blood, chorionic villi, amniotic fluid, and placenta for genotyping. Exome enrichment of genomic DNA libraries was performed using the TruSeq exome enrichment kit (Illumina) following the manufacturer's protocol. The genomic DNA libraries were sequenced for 75 bp in a paired-end format on a HiSeq 2000 instrument. Additional details are described in Materials and Methods in the online Supplemental Data file that accompanies this article.
DATA ALIGNMENT AND ANALYSIS
For RNA-seq, the sequenced reads were preprocessed and aligned to the hg19 reference human genome by an in-house bioinformatics pipeline. For exome-enriched genomic DNA library sequencing, the sequenced reads were aligned to the hg19 reference human genome by the Short Oligonucleotide Alignment Program 2 (22 ) . The detailed bioinformatics workflow and data analysis are described in Materials and Methods in the online Supplemental Data file and in online Supplemental Figs. 1 and 2.
IDENTIFICATION OF FETAL-AND MATERNAL-DERIVED
TRANSCRIPTS
To identify whether the plasma RNA transcripts were of fetal or maternal origin, we examined approximately one million SNPs in the dbSNP Build 135 database (23 ) that were located in the exons. For the following description, we use "A" and "B" to refer to alleles for a particular SNP site. We first sorted for informative SNPs containing fetal-specific alleles, i.e., the fetus was heterozygous (AB) and the mother was homozygous (AA), and for informative SNPs containing maternalspecific alleles, i.e., the fetus was homozygous (AA) and the mother was heterozygous (AB). We then sought these SNP alleles in the RNA transcripts (12 ) of the placenta, blood cells, and plasma. Because this analysis could potentially be confounded by ASE (24, 25 ) , we filtered out fetal-and maternal-derived transcripts in the plasma, which had evidence of allelic imbalances in the placenta and in the maternal blood cells, respectively. For the early pregnancy cases, RNA-seq was not performed on chorionic villi and amniotic fluid, because these samples had been exhausted for the genotyping analysis. Data sets of the 2 early pregnancy cases and the 2 late pregnancy cases were combined, respectively, to increase the number of informative SNPs for analysis. A detailed description is included in Materials and Methods in the online Supplemental Data file.
Results
RNA-SEQ DATA
After removal of duplicated reads and rRNA reads, a mean of 3 million analyzable reads were obtained for each nonpregnant female plasma sample, and a mean of 12 million analyzable reads were obtained for each plasma sample of pregnant women. For tissue RNAseq, an average of 173 million and 41 million analyzable reads per sample were obtained for placenta and blood cells, respectively. The RNA-seq alignment statistics are summarized in online Supplemental Table 2 . The GC content of sequenced reads was also examined in all samples (see Results in the online Supplemental Data file, online Supplemental Table 3 , and online Supplemental Fig. 4 ).
IDENTIFICATION AND ESTIMATION OF FETAL-AND MATERNAL-DERIVED TRANSCRIPT IN MATERNAL PLASMA
Informative genes, defined as genes with at least 1 informative SNP, were first identified based on the genotyping data. In the 2 early pregnancy cases, a total of 6714 and 6753 informative genes were available to examine the relative proportions of fetal and maternal contributions, respectively (see online Supplemental Table 4 ). In the 2 late pregnancy cases, a total of 7788 and 7761 informative genes were available to examine the relative proportions of fetal and maternal contributions, respectively. To measure the relative proportion of fetal contribution in the maternal plasma, we sorted for RNA transcripts for which the fetal-specific alleles were covered by at least 1 RNA-seq read in the maternal plasma samples. The relative proportions of such fetalderived transcripts were 3.70% and 11.28% during early and late gestations, respectively. Using a similar approach, we estimated the relative proportions of maternal contribution in the circulation, examined using the maternal-specific SNP alleles, to be 76.90% and 78.32% during early and late gestations, respectively (Fig. 1A) .
To further identify circulating transcripts that have a high level of fetal or maternal contribution, we first calculated the allele ratio as follows:
The B-allele refers to fetal-and maternal-specific alleles and the A-allele refers to the shared allele between the fetus and the mother. Theoretically, for a plasma transcript that is contributed solely by the fetus or by the mother, the B-allele ratio should be 0.5, assuming no ASE. In this study, we defined the B-allele ratio cutoff as Ն0.4 for an RNA transcript with high fetal or maternal contribution. This cutoff also took into consideration the Poisson distribution and random sampling of RNA-seq reads (details are described in Materials and Methods in the online Supplemental Data file). Using these criteria, 0.91% of the circulating transcripts were found to show high contribution by the fetus during early gestation (i.e., the first and second trimesters). This percentage increased to 2.52% during late gestation (i.e., the third trimester). On the other hand, 42.58% and 50.98% showed high contribution by the mother during early and late gestations, respectively ( Fig.  1A ; also see online Supplemental Table 4) .
We further examined the 112 SNPs on RNA transcripts with high fetal contributions (see online Supplemental Table 4A ) in the pre-and postdelivery maternal plasma samples. In this subset, 55.36% of the SNPs were devoid of RNA-seq reads in the postdelivery maternal plasma samples. As for the remaining 44.64%, fetal-specific alleles were not detected in the postpartum maternal plasma samples (Fig. 1B) . In the subset of 3002 SNPs with high maternal contribution (see online Supplemental Table 4A ), 20.85% were undetected in the postpartum maternal plasma (Fig. 1B) .
expression pattern for a given gene would be retained when the RNA transcripts were released from the tissues into the circulation, and hence could be detected in the plasma. In this study, we have examined the allelic counts of 2 RNA transcripts, namely PAPPA, a pregnancy-specific gene, and H19, an imprinted maternally expressed gene (27, 28 ) .
For the PAPPA gene, we analyzed an SNP, rs386088, which contains a fetal-specific SNP allele ( Table 1) . The absence of pregnancy-associated plasma protein A, pappalysin 1 (PAPPA) 5 RNA-seq reads in the postdelivery plasma samples indicated that it was indeed pregnancy specific (9 ) . Of note, there was no statistically significant difference in the proportions of fetalallele read counts between the predelivery maternal plasma and the placental RNA samples (P ϭ 0.320, 2 test), indicating that the maternal plasma data reflected the biallelic expression pattern of PAPPA in the placenta.
We recently reported that the DNA methylation pattern of the imprinted maternally expressed H19, imprinted maternally expressed transcript (nonprotein coding) (H19) gene in the placenta and the maternal blood cells could be detected by bisulfite DNA sequencing of maternal plasma DNA (29 ) . Here, we further examined whether the genomic imprinting status of the H19 gene could be explored at the RNA level. We first focused on an SNP site in exon 1 of the H19 gene, rs2839698, which contains a maternalspecific allele, i.e., AA in the fetus and AG in the mother. Only the G-allele was detected in the postdelivery maternal plasma (Table 2) . Such a monoallelic pattern was in accordance with its linkage to the unmethylated G-allele on the rs4930098 SNP site in the imprinting control region (see Results in the online Supplemental Data file and online Supplemental Fig.  5 ). In the predelivery maternal plasma, while the G-allele was present, the A-allele, which was contributed by the placenta, was also detected (Table 2 ). In 3 other SNP sites, i.e., rs2839701, rs2839702, and rs3741219, which bear maternal-specific alleles, a similar allelic pattern was found, i.e., biallelic in the predelivery maternal plasma and monoallelic in the postdelivery maternal plasma (Table 2 ). It might be that the maternal-specific alleles on these SNP sites were in the same maternal haplotype, which was unmethylated and was therefore transcribed. Notably, H19 RNA was not expressed in the maternal blood cells ( Table 2 ), suggesting that the H19 RNA molecules in the plasma were derived from maternal tissues/organs other than the blood cells. Nonplacental and nonfetal tissues that have been reported to show H19 expression included the adrenal gland, skeletal muscles, uterus, adipocytes, liver, and pancreas (30 ) .
IDENTIFICATION OF PREGNANCY-ASSOCIATED TRANSCRIPTS IN
MATERNAL PLASMA TRANSCRIPTOMES
A subset of circulating RNA transcripts bearing fetalspecific alleles completely disappeared from the mater- nal plasma after delivery (Fig. 1B) . These transcripts were considered to be fetal-specific in maternal plasma. On the other hand, a portion of maternal-specific alleles was also undetectable after delivery. Thus, we explored genes that showed upregulation during pregnancy, termed pregnancy-associated genes, by directly comparing their representation in the pre-and postdelivery maternal plasma. We defined pregnancyassociated genes as those that were detected in the predelivery plasma of the third-trimester pregnant women and those in which the postpartum plasma level was decreased by Ն2-fold. By using a bioinformatics algorithm for data normalization and differential gene expression analysis (for details see Materials and Methods in the online Supplemental Data file that accompanies this article), we compiled a list of 131 pregnancy-associated genes (see online Supplemental Table 7 ). Among these genes, 15 were previously reported to be pregnancy specific in maternal plasma (2-5, 9, 12, 14 ) . Using one-step real-time reverse transcriptase-PCR, we have further validated the pregnancy association of 5 newly identified transcripts, which were abundant in predelivery maternal plasma, i.e., signal transducer and activator of transcription 1, 91kDa (STAT1), guanylate binding protein 1, interferoninducible (GBP1), and hydroxysteroid (17-beta) dehydrogenase 1 (HSD17B1) in 10 additional plasma samples from third-trimester pregnant women, as well as keratin 18 (KRT18) and growth arrest and DNAdamage-inducible, gamma (GADD45G) in 10 plasma samples from another cohort of third-trimester pregnant women (see online Supplemental Fig. 6 ).
To assess the association of these 131 genes with pregnancy, hierarchical clustering was performed for all the plasma samples. A clear separation was observed between the plasma samples from pregnant women (i.e., early and late pregnancy) and those not associated with ongoing pregnancy (i.e., nonpregnant controls and postdelivery women) (Fig. 2) .
Interestingly, when the expression patterns of these 131 genes were compared between the plasma samples of the 2 late-pregnancy cases and their corresponding placenta and maternal blood cells, a closer resemblance was observed between the placenta and the predelivery plasma samples and between the maternal blood cells and the postpartum plasma samples (Fig. 3A) . This observation supports the thesis that most pregnancy-associated genes in maternal plasma are preferentially expressed in the placenta rather than in the maternal blood cells. Furthermore, the expression levels of these pregnancy-associated transcripts in the placentas and maternal plasma were positively correlated (P Ͻ 1eϪ16, Spearman correlation ϭ 0.68) (Fig. 3B) .
We further studied the 131 pregnancy-associated genes to determine whether they were derived from the 
a The shared A-allele was imprinted while the maternal-specific G-allele was transcribed. Details of the methylation status are shown in online Supplemental Fig. 5 .
fetus or the mother by analyzing the informative SNPs. The relative proportions of fetal and maternal contributions within these transcripts that contained informative SNPs were then computed. In late pregnancy, a larger proportion of these genes was found to exhibit predominant fetal contribution (Fig. 4A ) than when all circulating transcripts in the plasma were considered (Fig. 1A) . On the other hand, a smaller proportion of these 131 genes showed predominant maternal contribution than when all circulating transcripts were taken into account (Figs. 1A and 4A ). These results suggested that the representations of placenta-or fetal-derived transcripts were enriched among transcripts that were deemed as pregnancy associated. Although we were able to catalog a panel of pregnancy-associated genes through direct examination of the pre-and postdelivery maternal plasma samples, we also mined the placental and blood cell RNAseq data for comparison purposes. Assuming that pregnancy-associated genes should be those that were expressed at a high level in the placenta and at a low level in the maternal blood cells (3, 8 ) , we arbitrarily set a 20-fold difference as a minimum cutoff for the tissuebased analysis. This tissue-based analysis yielded a total of 798 candidate genes, in which the proportions of fetal and maternal contributions in the maternal plasma were calculated. A relatively high proportion of genes with predominant fetal contribution was identified (Fig. 4B ) compared to that of the full transcriptome (Fig. 1A) . However, the plasma-based strategy outperformed the tissue-based strategy in being able to identify a higher proportion of genes with predominant fetal contribution (Fig. 4) .
Discussion
In this work, we aimed to develop a technology for providing a global view of the transcriptomic activities in maternal plasma using RNA-seq. We have previously shown that the fractional fetal DNA concentration in maternal plasma can be calculated by targeting one or several fetal-specific loci because the whole fetal genome is evenly represented in the maternal plasma (31 ) . Unlike circulating DNA, measurement of the proportion of fetal-derived RNA transcripts in the maternal plasma is less straightforward because it is complicated by differential gene expression in the fetal and maternal tissues and perhaps their release into the circulation. By performing RNA-seq on maternal plasma and examining the polymorphic differences between the fetus and the mother, we were able to estimate the proportion of plasma transcripts contributed by the fetus. While maternal-derived transcripts dominated the plasma transcriptome, as one would anticipate, 3.70% and 11.28% of the circulating transcripts in the maternal plasma were derived from the fetus during early and late pregnancy, respectively. These fetalderived transcripts included the RNA molecules contributed by both the fetus and the mother, as well as those contributed solely by the fetus. We found the latter to constitute 0.90% and 2.52% of the maternal circulating transcripts, during early and late pregnancy, respectively. The higher representation of such fetal-specific genes during late pregnancy is perhaps correlated with an increase in the size of the fetus and the placenta as pregnancy progresses.
In this study, we have demonstrated that a balanced RNA allelic expression of the pregnancy-specific PAPPA gene in the placenta and the monoallelic expression of the imprinted maternally expressed H19 gene can be observed in the maternal plasma. These By performing RNA-seq directly on the pre-and postdelivery maternal plasma, we identified 131 pregnancy-associated genes. When hierarchical clustering was performed using these 131 genes, the different plasma samples (identified by case numbers on the x axis) were correctly classified. Log 2 (transcript levels) are shown. data suggest that the maternal plasma can be used as a noninvasive sample source for the study of allele expression patterns.
By quantitative comparison of the RNA transcripts in the pre-and postdelivery maternal plasma samples, we have compiled a list of 131 genes that were upregulated during pregnancy, as evident by their reduced representation in the postpartum plasma samples. As expected, the profiles of these genes could be used to differentiate plasma samples of pregnant women from those of nonpregnant women. Such direct comparison of the pre-and postdelivery maternal plasma samples has allowed us to, in a highthroughput manner, sort out pregnancy-associated genes, which may not necessarily be expressed at a much higher level in the placenta than in the maternal blood cells, as demonstrated in previous work (3, 8 ) . In essence, this direct plasma examination method presents a powerful approach for the discovery of circulating pregnancy-associated RNA transcripts, without a priori knowledge of the transcriptomic profiles of the placental tissues and the blood cells.
Although we have shown that RNA-seq is a feasible method to profile the plasma transcriptome, several technical issues can be further improved. First, the information yield for plasma RNA-seq could be increased by further optimization of the sequencing protocol, particularly in depletion of the highly transcribed rRNA and globin genes from the plasma. Second, we have focused only on the reference transcripts and have not yet explored individual isoforms. Future studies could include detection of novel transcripts and differential analysis of the splicing variants and their isoforms (32) (33) (34) by increasing the sequencing read depth. Third, we have omitted ASE filtering in the analysis of proportions of fetal-and maternal-derived transcripts for the early pregnancy samples, because the chorionic villi and amniotic fluid had been exhausted for the genotyping analysis. Nonetheless, we have shown in late pregnancy that ASE filtering had no pronounced impact on the identification of genes with predominant fetal and maternal contributions in the maternal plasma (see online Supplemental Table 4 , A and B). It is also worth mentioning that systematic errors associated with the MPS platforms, including but not limited to the Illumina system, have been reported (35, 36 ) . Thus, one would need to be mindful of the limitations of the adopted RNA-seq protocol and bioinformatics interpretation. Validation of the results using independent methodologies is of value.
In conclusion, we have demonstrated that RNAseq technology can be used to measure the proportion of fetal-derived transcripts and to identify circulating pregnancy-associated genes in the maternal plasma. This study has paved the path toward better comprehension of the transcriptomic landscape of maternal plasma, hence facilitating the identification of biomarker candidates involved in pregnancy-related diseases. We envision that this technology will lead to new avenues for molecular diagnostics for pregnancy-or placenta-related diseases and also for other diseases such as cancer (37 ) . 
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